“Candidate NVX -CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK),” the message said.
The medicine was also tested on the ‘British’ strain of coronavirus. On the basis of the tests, it is established that Novavax vaccine’s efficacy is 95.6% against the main strain and 85.6% against the new mutation. Over 15,000 participants at the age of 18 up to 84 were involved in the trial, including 27% of people over the age of 65.
Earlier, Novavax reported the positive results of the early testing of its vaccine from Covid-19 that showed that it might cause the immune response and it is safe in general.
As we reported, the European Medicines Agency (EMA) has approved AstraZeneca Covid-19 vaccine for use in the EU. The final decision on the use of this vaccine in the EU member states must be made by the European Commission.
Watch review of Year 2020 here: